The Use of B-type Natriuretic Peptide (BNP) to Predict Closure of a Patent Ductus Arteriosus (PDA) in Premature Infants

University of Virginia

Status: Completed

Conditions: Indomethacin Therapy; Patent Ductus Arteriosus

Treatments: Procedure: Withhold standard INDO dose if BNP < 100 pg/ml

Study type: Interventional

Funder types: Other

Identifiers

NCT00500305

10946

Details and patient eligibility

About

A patent ductus arteriosus (PDA) is associated with increased morbidity in premature infants. Standard indomethacin treatment is associated with intestinal and renal morbidity. B-type natriuretic peptide is elevated in significant PDAs. This study will determine whether BNP guided therapy could reduce doses of indomethacin.

Enrollment: 60 patients

Sex: All

Ages: Under 4 months old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Infants with echocardiographically confirmed PDA
• Infants determined by attending physician to require PDA closure

Exclusion criteria

• infants with congenital hearts disease
• infants with creatinine value > 2.0

Trial design

Primary purpose: Diagnostic

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)